v3.26.3
Fair Value Measurements - Narrative (Details)
$ in Thousands
 3 Months Ended 9 Months Ended
Dec. 31, 2022
USD ($)
Sep. 30, 2026
USD ($)
Jun. 30, 2026
USD ($)
Sep. 30, 2025
USD ($)
Dec. 31, 2022
USD ($)
Sep. 30, 2026
USD ($)
Sep. 30, 2025
USD ($)
Mar. 31, 2024
USD ($)
Mar. 28, 2024
USD ($)
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]                  
Issuance of common stock from exercise of stock options   $ 2,540       $ 9,950      
Issuance of common stock in cash       $ 14,370   404,912 $ 14,370    
ES Therapeutics, LLC | Derivative liability                  
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]                  
Initial valuation of warrant liability         $ 5,000        
AlmataBio Transaction                  
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]                  
Contingent consideration               $ 5,000  
Contingent consideration   0              
AlmataBio Transaction | Milestone Three                  
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]                  
Contingent consideration     $ 15,000         $ 15,000  
Issuance of common stock from exercise of stock options     $ 2,250            
License agreement term     90 days            
Issuance of common stock in cash     $ 5,125            
Milestone cash payment (as a percent)     0.50            
Milestone equity payment (as a percent)     0.50            
Collaborative arrangement, trading day     20 days            
Contingent consideration     $ 6,600     6,600      
AlmataBio Transaction | Milestone One                  
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]                  
Contingent consideration                 $ 5,000
AlmataBio Transaction | Milestone Two                  
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]                  
Contingent consideration     $ 15,000           $ 15,000
AVTX-501                  
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]                  
Maximum aggregate milestone payment $ 20,000       20,000        
AVTX-501 | Derivative liability                  
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]                  
Initial valuation of warrant liability         $ 3,500        
Contingent consideration   100       100      
AVTX-501 | Derivative liability | Measurement Input, Probability Of Success                  
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]                  
Derivative liability, measurement input 0.01       0.01        
Derivative liability, measurement input, term 10 years 6 months                
AVTX-007 | Derivative liability                  
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]                  
Initial valuation of warrant liability         $ 1,300        
Contingent consideration   18,300       18,300      
AVTX-007 | Derivative liability | Measurement Input, Probability Of Success                  
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]                  
Derivative liability, measurement input 0.41       0.41        
AVTX-007 | Derivative liability | Measurement Input, Sales Forecast Peak                  
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]                  
Change in fair value of warrant liability         $ 1,800,000        
AVTX-007 | Derivative liability | Measurement Input, Expected Term                  
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]                  
Derivative liability, measurement input, term         6 years        
AVTX-007 | Derivative liability | Recurring Basis                  
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]                  
Contingent consideration   18,200       18,200      
AVTX-007 | Milestone One                  
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]                  
Maximum aggregate milestone payment $ 6,250       $ 6,250        
AVTX-007 | Milestone Two                  
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]                  
Maximum aggregate milestone payment $ 67,500       $ 67,500        
Royalty payments period 10 years       10 years        
AVTX-611                  
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]                  
Maximum aggregate milestone payment $ 20,000       $ 20,000        
AVTX-501 And AVTX-007 | Derivative liability                  
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]                  
Initial valuation of warrant liability         $ 4,800        
Change in fair value of derivative liability   $ (200)       $ 300